JohnKorethMD

Oncology • Boston, MA

Hematologic Oncology

Assistant Professor, Medicine, Brigham & Women's Hospital, Harvard Medical School

Join to view full profile

Dr. Koreth is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Koreth's full profile

Already have an account?

Office
44 Binney St
# D1B22
Boston, MA 02115
Phone+1 617-632-2949

Fax+1 617-632-5168

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2000 - 2004
Brigham and Women's HospitalResidency, Internal Medicine, 1998 - 2000
Maulana Azad Medical CollegeClass of 1993

Certifications & Licensure

CA State Medical License 2008 - Present
MA State Medical License 2001 - 2026
ME State Medical License 2022 - 2025
American Board of Internal Medicine Hematology

Clinical Trials

Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401) Start of enrollment: 2005 Dec 01
Completed
Phase 3
Ultra-Low Dose Interleukin-2 for Refractory Chronic Graft Versus Host Disease Start of enrollment: 2007 Aug 01
Completed
Phase 1
Infusion of Donor Lymphocytes Depleted of CD25+ Regulatory T-cells in Patients With Relapsed Hematologic Malignancies Start of enrollment: 2007 Dec 01
Completed
Phase 1
Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Disease Start of enrollment: 2008 Dec 01
Completed
Phase 2
Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors Start of enrollment: 2011 May 01
Completed
Phase 2
Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease
ACTIVE_NOT_RECRUITING
PHASE2
A Pilot Study of Alpha-1-Antitrypsin (AAT) in Steroid Refractory Acute Graft vs Host Disease Start of enrollment: 2013 Jul 01
Completed
Phase 2
Standard of Care vs. Bortezomib in Graft-Versus Host Disease After Hematopoietic Stem Cell Transplant Start of enrollment: 2013 Jan 01
Completed
Phase 2
Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease
ACTIVE_NOT_RECRUITING
PHASE1
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) Start of enrollment: 2014 Aug 01
Completed
Phase 2
A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT Start of enrollment: 2019 Jul 10
ACTIVE_NOT_RECRUITING
PHASE1
IS-free Treg HaploHCT Start of enrollment: 2021 Jan 12
RECRUITING
PHASE1
Join now to see all

Publications & Presentations

PubMed

Toward Improving Initial Therapy of Acute Graft Versus Host Disease.
Ansh Krishnachandra Mehta, John Koreth
American Journal of Hematology. 2025-05-01
First-in-human evaluation of memory-like NK cells with an IL-15 super-agonist and CTLA-4 blockade in advanced head and neck cancer.
Roman M Shapiro, Michal Sheffer, Matthew A Booker, Michael Y Tolstorukov, Grace C Birch
Journal of Hematology & Oncology. 2025-02-14
2 citations
Non-pathogenic E. coli displaying decoy-resistant IL18 mutein boosts anti-tumor and CAR NK cell responses.
Shaobo Yang, Michal Sheffer, Isabel E Kaplan, Zongqi Wang, Mubin Tarannum
Nature Biotechnology. 2024-10-04

Journal Articles

Small-Molecule BCL6 Inhibitor Effectively Treats Mice with Non-Sclerodermatous Chronic Graft-Versus-Host Disease
Joseph H Antin, Bruce Blazar, Leo Luznik, John Koreth, Ivan Maillard, Robert J Soiffer, James E Bradner, Jonathan S Serody, Jerome Ritz, Blood

Press Mentions

Equillium Announces Positive Topline Results from the EQUATE Study in First-Line Treatment of Acute Graft-Versus-Host DiseaseJune 11th, 2021
Equillium Announces Oral Presentation Highlighting Positive Data from the EQUATE Study in Acute Graft-Versus-Host Disease at the EHA2021 Virtual Congress of the European Hematology AssociationMay 13th, 2021
Equillium Presents Positive Interim Clinical Data of Itolizumab in First-Line Treatment of Acute Graft-Versus-Host Disease at the 2021 Transplantation and Cellular Therapy Meetings Digital ExperienceFebruary 12th, 2021
Join now to see all